您现在的位置: 首页> 研究主题> 蛋白激酶CK2

蛋白激酶CK2

蛋白激酶CK2的相关文献在1998年到2019年内共计81篇,主要集中在生物化学、药学、基础医学 等领域,其中期刊论文81篇、专利文献537967篇;相关期刊47种,包括吉首大学学报(自然科学版)、医学分子生物学杂志、国际病理科学与临床杂志等; 蛋白激酶CK2的相关文献由108位作者贡献,包括刘新光、梁念慈、林小聪等。

蛋白激酶CK2—发文量

期刊论文>

论文:81 占比:0.02%

专利文献>

论文:537967 占比:99.98%

总计:538048篇

蛋白激酶CK2—发文趋势图

蛋白激酶CK2

-研究学者

  • 刘新光
  • 梁念慈
  • 林小聪
  • 陈小文
  • 李春梅
  • 黄功华
  • 阮杰
  • 伍钢
  • 刘文
  • 周方正
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 尤信信
    • 摘要: 蛋白激酶CK2具有组成型活化功能.目前已知CK2作用底物超过300种,涉及细胞生长、增殖、分化、凋亡及信号转导等.此外,CK2通过抑制细胞非正常凋亡而在细胞生命活动中扮演重要角色,确保细胞在炎症或病毒入侵环境下存活.该文综述了CK2的抗炎和抗病毒作用.
    • 尤信信(综述)1; 刘新光(审校)1
    • 摘要: 蛋白激酶CK2具有组成型活化功能。目前已知CK2作用底物超过300种,涉及细胞生长、增殖、分化、凋亡及信号转导等。此外,CK2通过抑制细胞非正常凋亡而在细胞生命活动中扮演重要角色,确保细胞在炎症或病毒入侵环境下存活。该文综述了CK2的抗炎和抗病毒作用。
    • 徐宛婷; 王浩; 刘畅; 罗英花; 朴仙姬; 金成浩
    • 摘要: 多发性骨髓瘤(MM)是一种恶性浆细胞病,发病后导致组织器官损伤和骨破坏,具有较高的死亡率.蛋白激酶CK2(酪蛋白激酶)是真核生物中普遍存在的丝氨酸/苏氨酸蛋白激酶,在肿瘤细胞增殖和血液肿瘤中起重要作用.CK2在恶性血液病包括慢性、急性白血病和多发性骨髓瘤中有致瘤作用,可通过调节多种关键的信号通路促进恶性肿瘤的生长.该文综述了CK2在多发性骨髓瘤中对NF-κB和STAT3信号通路及内质网应激(ERS)、未折叠蛋白反应(UPR)和热休克蛋白90的调节作用,并讨论其作为MM治疗靶点的可行性,为MM的预防及治疗提供理论依据.
    • 敖英; 张杰; 李枫; 金美玲
    • 摘要: Protein kinase CK2α was knocked out in human colorectal cancer cell line HCT116 by using CRISPR-Cas9 gene editing technique to investigate CK2α's function.PX459-g CK2α vector was successfully transfected into HCT116 cells,and screened gene knockout cell line to further analysis whether it was involved in the proliferation and migration of cancer cells.The results show that HCT116 cell line with ck2α knockout is successfully obtained by CRISPR-Cas9 gene editing technique.ck2α knockout can significantly reduce the cell proliferation rate and migration ability,and accelerate the process of cellular senescence.%运用CRISPR-Cas9基因编辑技术,在人结肠癌细胞株HCT116中敲除蛋白激酶基因ck2α,利用敲除细胞系研究CK2参与结肠癌调控的分子机制.通过构建PX459-g CK2α载体成功转染HCT116细胞,筛选出基因完全敲除的细胞系,考察其是否参与癌细胞增殖和迁移能力.结果显示,利用CRISPR-Cas9基因编辑技术可成功获得ck2α完全敲除的HCT116细胞系,ck2α敲除后细胞的增殖率和迁移能力显著降低,细胞的衰老进程加快.
    • 张静; 闫新玲; 马遇庆; 罗丹; 张亚静
    • 摘要: Objective:To study expression CK2 、SFRP2 that were key genes of Wnt signaling pathway in kazak in esophageal cancer.Methods:From 2007 to 2014 in pathologically confirmed primary esophageal squamous cell carcinoma in 75 kazak cases,75 cases of adjacent tissue.CK2 、SFRP2 were detected by immunohistochemical method in esophageal squamous cell carcinoma and adjacent tissue.And collect the clinical data of 75 patients,To obtain relevant pathological parameters,the application of statistical methods to explore the relationship between CK2 、SFRP2 and other clinical data.Results:(1) The high expression of CK2 in esophageal carcinoma,The low expression of SFRP2 in esophageal cancer tissues,The low expression of CK2 in esophageal carcinoma adjacent tissue,The high expression of SFRP2 in esophageal cancer tissues adjacent tissue(P < 0.05),CK2 was associated with invasion depth (P < 0.05).CK2 was not associated with other clinical parameters(P > 0.05),the expression of SFRP2 was not associated the nationality,age,gender,tumor location,tumor size,lymph node metastasis,degree of differentiation,depth of invasion,vascular nerve invasion parameter (P >0.05) CK2 is negatively related to SFRP2 (P < 0.05).Conclusion:CK2 、SFRP2 in Wnt pathways may adjust the occurrence and development of esophageal cancer.which may be a potential molecular target for the treatment of esophageal cancer.%目的:探讨Wnt信号通路上关键基因CK2和SFRP2在哈萨克族食管癌中的表达意义.方法:选取2007 ~ 2014年经手术病理证实为哈萨克族原发性食管鳞癌患者75例,癌旁组织75例.采用免疫组化方法检测食管鳞癌及癌旁组织中CK2、SFRP2的蛋白表达,结合患者临床资料,获得相关病理参数,应用统计学方法,探讨二者在Wnt信号通路上的相互作用及与其他临床资料的关系.结果:(1)食管鳞癌组织中CK2高表达、SFRP2低表达,癌旁组织中SFRP2高表达、CK2低表达(P<0.05),临床病理参数方面CK2的表达与肿瘤浸润深度相关(P<0.05),与其他临床病理参数无关.SFRP2表达与民族、年龄、性别、肿瘤部位、肿瘤大小、淋巴结转移、血管神经侵犯不相关(P>0.05).CK2和SFRP2在哈萨克族食管鳞癌组织中的表达呈负相关(P<0.05).结论:CK2、SFRP2在Wnt信号通路上可能参与食管癌的发生、发展;CK2、SFRP2可能是治疗食管癌的潜在分子靶点.
    • 黄世杰
    • 摘要: Senhwa生物科学公司宣布FDA授予CX-4945治疗晚期肝小胆管癌的罕见病药设计认可。该药是新一代小分子药物,抑制蛋白激酶CK2,在癌细胞DNA损害的修复机制中具有重要作用。
    • 张盛; 李倩雯; 李珂; 周方正; 李振宇; 董晓荣; 刘莉; 伍钢; 孟睿
    • 摘要: Objective To evaluate the effect of a protein kinase CK2 inhibitor on intracellular levels of reactive oxygen species and DNA double⁃stand break in human non⁃small cell lung cancer H460 cells. Methods H460 cells were exposed to 0, 125, 25.0, and 50.0μmol/L quinalizarin, a specific inhibitor of protein kinase CK2, for 24 hours. The changes in protein and mRNA levels of CK2 subunits were measured. Flow cytometry was used to measure changes in the intracellular levels of reactive oxygen species in H460 cells after 4 or 24 hours of quinalizarin treatment. Immunofluorescence assays were performed to determine the effect of the CK2 inhibitor onγ⁃H2 AX expression and the average fluorescent number ofγ⁃H2 AX foci in H460 cells. Comparison was made by analysis of variance and t test. Results There were no significant differences in protein or mRNA levels of CK2 subunits in H460 cells after quinalizarin treatment ( CK2α,0μmol vs. 125 μmol/L, P=0966;0 μmol/L vs. 25 μmol/L, P=0355;0 μmol/L vs. 50 μmol/L, P=0864, CK2α’ , 0 μmol/L vs. 125μmol/L,P=0409;0μmol/L vs. 25μmol/L,P=0833;0μmol/L vs. 50 μmol/L, P=00. 746, CK2β, 0 μmol/L vs. 125 μmol/L, P=0532;0 μmol/L vs. 25 μmol/L, P=0830;0 μmol/L vs. 50 μmol/L, P= 0061 ) . The intracellular levels of reactive oxygen species were substantially elevated in H460 cells with the increase in quinalizarin concentration and treatment time. Different concentrations of quinalizarin resulted in dose⁃and time⁃dependent increases in the numbers of γ⁃H2 AX foci after 4 and 24 hours of treatment ( treated by Quianlizarin for 4 or 24 h, 0 μmol/L vs. 125μmol/L,125 μmol/L vs. 25 μmol/L, 25 μmol/L vs. 50 μmol/L, all P=0000, concentration is 125μmol/L,25 μmol/L or 50 μmol/L, 4 h vs. 24 h, all all P=0000 ) . Conclusions Quinalizarin can increase the intracellular levels of reactive oxygen species and DNA double⁃stand break in H460 cells by inhibition of protein kinase CK2 activity. This study provides a theoretical basis for using quinalizarin as a potential radiosensitizer for lung cancer.%目的:观察蛋白激酶CK2抑制剂对人肺癌细胞系H460细胞内活性氧水平及DNA双链断裂损伤的影响。方法使用终浓度为0、125、250、500μmol/L的蛋白激酶CK2抑制剂醌茜素分别作用H460细胞24 h,检测CK2各亚基蛋白及mRNA水平变化。不同浓度梯度醌茜素作用4、24 h后,采用流式细胞仪检测H460细胞内活性氧水平变化。通过免疫荧光法检测CK2抑制剂对H460细胞γ⁃H2 AX表达的影响,并计算细胞内γ⁃H2 AX焦点的平均值。采用方差分析和t检验。结果醌茜素对H460细胞 CK2各亚基蛋白或 mRNA 水平无明显影响( CK2α,0μmol ∶125μmol/L, P=0966;0μmol/L ∶25μmol/L,P=0355;0μmol/L ∶50μmol/L,P=0864, CK2α’,0μmol/L ∶125μmol/L,P=0409;0μmol/L ∶25μmol/L, P=0833;0μmol/L ∶50μmol/L, P=00.746, CK2β,0μmol/L ∶125μmol/L, P=0532;0μmol/L ∶25μmol/L, P=0830;0μmol/L ∶50μmol/L, P=0061)。随着醌茜素浓度增加及作用时间延长,H460细胞内活性氧水平明显升高。不同浓度醌茜素可增加细胞内γ⁃H2 AX焦点数,并呈剂量和时间依赖性(醌茜素作用时间4 h或24 h,0μmol/L ∶125μmol/L,125μmol/L ∶25μmol/L,25μmol/L ∶50μmol/L,P均=0000,浓度为125μmol/L,25μmol/L或50μmol/L,4 h ∶24 h,P均=0000)。结论醌茜素可通过抑制蛋白激酶CK2活性增加肺癌H460细胞内活性氧水平及DNA双链断裂损伤,该研究为醌茜素作为一种有潜力的肺癌放射增敏剂提供了理论基础。
    • 李珂; 周瑜; 张盛; 李倩文; 李振宇; 周方正; 伍钢; 孟睿
    • 摘要: 目的:研究蛋白激酶CK2抑制剂-醌茜素在非小细胞肺癌中的抗肿瘤作用,探讨蛋白激酶CK2成为非小细胞肺癌治疗新靶点的可能.方法:使用MTT法检测细胞增殖,研究醌茜素对非小细胞肺癌细胞A549、H460细胞增殖的影响,探究醌茜素作用于A549、H460增殖的可能途径.使用流式细胞术检测醌茜素作用于A549、H460后,细胞的凋亡以及周期的变化.使用Tram-well迁移实验检测细胞迁移能力,探究醌茜素对A549、H460迁移的影响.结果:醌茜素能够抑制A549、H460细胞的增殖,并且该抑制作用具有时间依赖性及浓度依赖性(P<0.01,P<0.01).在25 μmol· L-1及50 μmol·L-1浓度下,醌茜素能够促进细胞A549、H460凋亡(P<0.01,P<0.01;P<0.01,P<0.01).在实验条件下,醌茜素对A549的周期影响差异没有统计学意义,但醌茜素在50μmol· L-1浓度下对H460具有周期阻滞作用,G2/M期的比例明显增加(P<0.01).醌茜素能够显著抑制A549、H460细胞的迁移活动.结论:蛋白激酶CK2抑制剂-醌茜素能够抑制非小细胞肺癌细胞系A549、H460增殖、迁移,促进其凋亡,发挥抗肿瘤作用,有可能成为一种具有潜力的非小细胞肺癌分子靶向治疗的新型药物.
    • 李倩雯; 周瑜; 李珂; 李俊玉; 张盛; 周方正; 董佑红; 伍钢; 孟睿
    • 摘要: 目的 观察蛋白激酶CK2抑制剂对人类非小细胞肺癌细胞活力及迁移能力的影响及对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)埃克替尼(icotinib)的靶向增敏作用.方法 通过Western blot法检测蛋白激酶CK2各亚基在不同类型肺癌细胞株中的表达状态;免疫组织化学法检测CK2功能亚基在不同类型肺癌标本中得表达;采用噻唑蓝(MTT)法检测不同浓度梯度蛋白激酶CK2抑制剂醌茜素(Quinalizarin)对A549及H-460细胞活力的影响;同时用Transwell迁移实验检测其对这两种细胞迁移能力的影响;通过MTT法检测醌茜素与埃克替尼联合应用对不同EGFR表达状态的非小细胞肺癌细胞活力的影响.结果 通过检测蛋白激酶CK2在不同类型肺癌细胞株及肺癌标本中的表达,发现该激酶广泛表达于各类型肺癌中.使用0、12.5、25.0、50.0 μmol/L终质量浓度的醌茜素抑制激酶活性后,MTT实验检测发现,随浓度增高A549及H460细胞活力均有明显抑制(P<0.01);迁移实验中,随浓度增高A549细胞穿过人工基底膜的细胞数分别为(1041.0±115.9)、(705.3±74.7)、(451.3±55.0)、(128.3±38.0)个,H460穿过人工基底膜的细胞数分别为(924.0±65.6)、(593.7±69.2)、(954.7±24.7)、(193.0±27.2)个,均明显减少(P<0.01).埃克替尼与醌茜素联合应用分别处理A549、H1650、H1975、PC9细胞,与单独使用埃克替尼比较,在50.0、100.0 μmol/L浓度时,各细胞株细胞活力明显下降(P<0.01).结论 蛋白激酶CK2在各种类型肺癌中广泛表达,通过降低CK2的激酶活性可明显抑制非小细胞肺癌细胞活力及迁移能力,并可增强埃克替尼对不同EGFR表达状态的非小细胞肺癌细胞的抑制作用.%Objective To explore the effect of the protein kinase CK2 inhibitor on cell viability and migration of human non-small lung cancer cells and its enhanced role in sensitivity to Icotinib,one of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).Methods The protein expression of individual CK2 subunits in different lung cancer cells was measured by Western blotting.The protein expression of the catalytic subunit-CK2α in different types of lung cancer tissues was detected by immunohistochemistry.Methyl thiazol tetrazolium (MTT) assays and Transwell migration assays were applied to assess the effect of CK2 inhibitor Quinalizarin on cell viability and migration capabilities of A549 and H460 respectively.The effect of the combination of Icotinib and Quinalizarin on cell viability of non-small lung cancer cell lines in the presence or absence of EGFR mutation was examined by MTT assays.Results Western bolting and immunohistochemistry revealed that protein kinase CK2 was overexpressed in different types of lung cancer cells and tissues.Quinalizarin,a CK2 inhibitor,could inhibit the cell viability of A549 and H460 cells in a dose-dependent manner within the range between 12.5 and 50.0 μmol/L (P < 0.01).Along with the increased concentration of Quinalizarin,the migration of A549 and H460 was significantly suppressed (1 041.0 ± 115.9,705.3 ± 74.7,451.3 ± 55.0,128.3 ± 38.0 and 924.0 ± 65.6,593.7 ± 69.2,954.7 ± 24.7,193.0 ± 27.2,P < 0.01).The combination of Icotinib and Quinalizarin could inhibit the cell viability of A549,H1650,H1975 and PC9 as compared with Icotinib used alone in the concentrations of 50 and 100 μmol/L (P < 0.01).Conclusion Protein kinase CK2 was overexpressed in different types of lung cancer.Quinalizarin,one of the CK2 inhibitors can suppress the cell viability and migration capabilities of different types of lung cancer cells.It can also enhance the effect of Icotinib on cell viability of non-small lung cancer cell lines with or without EGFR mutation.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号